S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:MDGL

Madrigal Pharmaceuticals Stock Forecast, Price & News

$82.06
-3.08 (-3.62%)
(As of 11/26/2021 04:00 PM ET)
Add
Compare
Today's Range
$81.00
$84.64
50-Day Range
$74.23
$95.09
52-Week Range
$74.18
$142.62
Volume
92,983 shs
Average Volume
141,681 shs
Market Capitalization
$1.40 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.14
30 days | 90 days | 365 days | Advanced Chart
Receive MDGL News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Madrigal Pharmaceuticals logo

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Headlines

Madrigal Pharmaceuticals, Inc. (MDGL)
October 13, 2021 |  uk.finance.yahoo.com
Noteworthy Friday Option Activity: MDGL, GM, SWKS
September 24, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MDGL
CUSIP
87162T20
Employees
42
Year Founded
2011

Sales & Book Value

Annual Sales
N/A
Book Value
$13.74 per share

Profitability

Net Income
$-202.24 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
12,017,000
Market Cap
$1.40 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
11/27/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

Social Links


MarketRank

Overall MarketRank

2.45 out of 5 stars

Medical Sector

145th out of 1,391 stocks

Pharmaceutical Preparations Industry

62nd out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions

Is Madrigal Pharmaceuticals a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Madrigal Pharmaceuticals stock.
View analyst ratings for Madrigal Pharmaceuticals
or view top-rated stocks.

How has Madrigal Pharmaceuticals' stock price been impacted by Coronavirus?

Madrigal Pharmaceuticals' stock was trading at $81.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MDGL shares have increased by 1.2% and is now trading at $82.06.
View which stocks have been most impacted by COVID-19
.

When is Madrigal Pharmaceuticals' next earnings date?

Madrigal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Madrigal Pharmaceuticals
.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($3.79) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($3.87) by $0.08.
View Madrigal Pharmaceuticals' earnings history
.

What price target have analysts set for MDGL?

9 equities research analysts have issued 12-month target prices for Madrigal Pharmaceuticals' stock. Their forecasts range from $111.00 to $219.00. On average, they expect Madrigal Pharmaceuticals' share price to reach $179.50 in the next twelve months. This suggests a possible upside of 118.7% from the stock's current price.
View analysts' price targets for Madrigal Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Madrigal Pharmaceuticals' key executives?

Madrigal Pharmaceuticals' management team includes the following people:
  • Paul A. Friedman, Chairman, President & Chief Executive Officer
  • Alex G. Howarth, Chief Financial Officer
  • Rebecca A. Taub, Director & Chief Medical Officer
  • Brian J. Lynch, Senior Vice President & General Counsel
  • Remy Sukhija, Chief Commercial Officer & Senior Vice President

What other stocks do shareholders of Madrigal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Advaxis (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).

What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (5.95%), BlackRock Inc. (5.36%), Artisan Partners Limited Partnership (1.29%), Geode Capital Management LLC (1.18%), Dimensional Fund Advisors LP (1.02%) and Goldman Sachs Group Inc. (0.93%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc and Fred B Craves.
View institutional ownership trends for Madrigal Pharmaceuticals
.

Which institutional investors are selling Madrigal Pharmaceuticals stock?

MDGL stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Two Sigma Advisers LP, Renaissance Technologies LLC, Cubist Systematic Strategies LLC, Morgan Stanley, Millennium Management LLC, Parkman Healthcare Partners LLC, and Strs Ohio.
View insider buying and selling activity for Madrigal Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Madrigal Pharmaceuticals stock?

MDGL stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Goldman Sachs Group Inc., EP Wealth Advisors LLC, Point72 Asset Management L.P., Polar Asset Management Partners Inc., Altium Capital Management LP, Skandinaviska Enskilda Banken AB publ , and UBS Group AG.
View insider buying and selling activity for Madrigal Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Madrigal Pharmaceuticals' stock price today?

One share of MDGL stock can currently be purchased for approximately $82.06.

How much money does Madrigal Pharmaceuticals make?

Madrigal Pharmaceuticals has a market capitalization of $1.40 billion. The biopharmaceutical company earns $-202.24 million in net income (profit) each year or ($14.65) on an earnings per share basis.

How many employees does Madrigal Pharmaceuticals have?

Madrigal Pharmaceuticals employs 42 workers across the globe.

When was Madrigal Pharmaceuticals founded?

Madrigal Pharmaceuticals was founded in 2011.

What is Madrigal Pharmaceuticals' official website?

The official website for Madrigal Pharmaceuticals is www.madrigalpharma.com.

Where are Madrigal Pharmaceuticals' headquarters?

Madrigal Pharmaceuticals is headquartered at 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at (484) 380-9263, via email at [email protected], or via fax at 781-274-8228.


This page was last updated on 11/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.